摘要
急性肺损伤/急性呼吸窘迫综合征是临床常见的危重病症之一,起病急、发展快、病死率高,尽管在过去几年中,重症医学的发展使得ARDS的院内发生率和死亡率大幅下降,但目前临床上仍缺乏特效的治疗手段。肺保护通气、积极抗感染治疗和限制性液体管理是目前主要西医治疗策略,近年来有部分改进从而进一步降低该病的死亡率。此外,关于ARDS异质性的研究是近年来热点,期望找到可靠的生物标志物和适当的治疗靶点,更好地开展精准化治疗。随着医药治疗ARDS的实验和临床研究不断深入,中医药治疗ARDS也取得了一定的成果。本文回顾了近年来国内外相关文献,总结了中西医关于此病的最新研究治疗进展,以期为ALI/ARDS的临床个体化治疗和药物研发提供新思路。
Acute lung injury/acute respiratory distress syndrome is one of the common clinical critical illnesses.It has a rapid onset,rapid development,and high mortality rate.Although in the past few years,the development of intensive care medicine has led to a significant drop in the incidence and mortality of ARDS in the hospital.There is still a lack of clinically effective treatments.Lung-protective ventilation,active anti-infective treatment,and restrictive fluid management are currently the main Western medical treatment strategies.In recent years,some improvements have been made to reduce the mortality of this disease further.In addition,research on the heterogeneity of ARDS has been a hot spot in recent years,and it is hoped that reliable biomarkers and appropriate therapeutic targets can be found to better carry out the precision treatment.With the continuous deepening of experimental and clinical research on the medical treatment of ARDS,Chinese medicine treatment of ARDS has also achieved certain results.This article reviews the relevant domestic and foreign literature in recent years,summarizes the latest research and treatment progress of Chinese and Western medicine on this disease,in order to provide new ideas for individualized clinical treatment and drug development of ALI/ARDS.
作者
俞正秋
马春芳
蔡宛如
YU Zhengqiu;MA Chunfang;CAI Wanru(The Second Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China)
出处
《中国现代医生》
2021年第13期189-192,共4页
China Modern Doctor
基金
浙江省中医药科技计划重点研究项目(2017ZZ008)
国家自然科学基金青年科学基金项目(81603545)。
关键词
急性肺损伤
急性呼吸窘迫综合征
间充质干细胞
中医药
Acute lung injury
Acute respiratory distress syndrome
Mesenchymal stem cells
Traditional Chinese medicine
